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Summary: Apolipoproteins B and E were determined in 40 patients with type III hyperlipoproteinaemia
(familial dysbetalipoproteinaemia) and in 48 patients with other types of hyperlipoproteinaemia matched for
cholesterol and triacylglycerols. In type III patients, apolipoprotein E was increased and apolipoprotein B
was lower than in other types of hyperlipoproteinaemia. The apolipoprotein E to apolipoprotein B ratio
almost completely discriminated between type III and other types of hyperlipoproteinaemia. Assuming a cut-
off value of 0.09 for the apolipoprotein E to apolipoprotein B ratio, diagnostic sensitivity was 95% and
specificity was 88%. It is concluded that the apolipoprotein E to apolipoprotein B ratio represents the first-
line screening quantity of choice for the identification of patients with type III hyperlipoproteinaemia in the
clinical laboratory.
Introduction ones being normolipidaemic or even hypolipidaemic.
^ ... . t T T , t. . . . , This has led to the suggestion that further genetic,Familial type III hyperlipoproteinaemia is character- 4 , .. . ι * * · j. . . . i - r i _ i ι · -L χ metabolic, or environmental factors are required toizedby the accumulation of cholesterol-rich remnants ΤΤτ ι. ι· · · /- 0 4 < \* . , r " ,. , ', ,- r « , - express type III hyperlipoprotemaemia (1, 8 —11).derived from the partial catabolism of chylormcrons J* J* r
and very low density lipoproteins. Type III patients There is no simple test to establish the biochemical
are at high risk of developing premature coronary diagnosis of type III hyperlipoproteinaemia. Cur-
and peripheral atherosclerosis (1). rently, the following criteria are applied: cholesterol
Ώ .« .. „ TTT ^ ι- · · · and triacylglycerols are elevated to about the samePathogenetically, type III hyperlipoproteinaemia is ., ..ι * j * j r · ι · '/ ~ ' ' . extent, cutaneous xanthomas are present, lipoprotemrelated to dysfunctional isoforms of apolipoprotein , ' . , , , 0 * ·. * τ,τ ™-D i>r ΟΛΛΛΛ Γ + - n · * j · u electrophoresis reveals a broad -band, the VLDL-E, a MT 34000 glycoprotem normally associated with * , A , Α ι .· 1 1 , r i /nι Λ ·* A·'iTj · "Ί- - ,\ A^ cholesterol to plasma tnacylglycerol [mmol/1] ratiovery low density and high density lipoproteins (1—4). j Λ *·« « · · · ι r j - u\ *t ΛΛΟ/ * τττ - ι_ exceeds 0.68, -migrating particles are found in theMore than 90% of type III patients are homozygous ,Tr ^T r . K Λ r * · r? u
Γ ., v '. . . ~ f " c i_. i j VLDL fraction, and the apolipoprotein E phenotypefor the apolipoprotein E2 isoform which does not . /2 F K K κ jv
bind normally to apolipoprotein B,E-receptors (5 — 7), '
and this accounts for the impaired clearance of rem- However, none of these criteria is compelling. Cho-
nants in type III hyperlipoproteinaemia. However, the lesterol and triacylglycerols may vary widely in and
apolipoprotein E2/2 phenotype is much more frequent among type III subjects. Cutaneous xanthomas occur
than type III hyperlipoproteinaemia. Only one in 20 in only about 50% of the patients, and the demon-
apolipoprotein E2/2 homozygotes will actually de- stration of a broad -band in agarose gel electropho-
velop type III hyperlipoproteinaemia, the remaining resis of whole plasma is often misleading. Obviously,
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the most reliable markers for type III hyperlipopro-
teinaemia are an increased VLDL-cholesterol to
plasma triacylglycerol ratio, the demonstration of ß-
VLDL, and apolipoprotein E2/2 homozygosity.1) This
means that laboratory diagnosis of type III hyperli-
poproteinaemia depends on sophisticated methods
such as ultracentrifugation and apolipoprotein E
phenotyping which are usually available to specialized
laboratories only.
On the other hand, there are several points calling for
a simple way to recognize type III hyperlipoprotein-
aemia in the clinical setting. Firstly, affected patients
carry a tremendous risk of developing coronary artery
disease and peripheral vascular disease. Secondly, the
diagnosis of type III hyperlipoproteinaemia has a
considerable therapeutic impact. Type III patients
usually respond well to the elimination of disease
promoting factors and/or to dietary treatment, and
once lipoprotein metabolism has been normalized,
former type III patients may even be protected from
premature atherosclerosis due to the low concentra-
tion of LDL found in normolipidaemic E2 homozy-
gotes (1).
It has been known for a long time that apolipoprotein
E concentrations are increased in type III hyperlipo-
proteinaemia (12), whereas apolipoprotein B is nor-
mal or low. Nowdays, both apolipoprotein E and
apolipoprotein B can easily be quantified by auto-
mated methods. We have therefore studied the rele-
vance of apolipoprotein E and apolipoprotein B de-




Fasting blood samples were drawn into tubes containing EDTA
• K2 al a final concentration of 1.5 — 2.0 g/1 (Sarstedt, Nurn-
brecht, Germany). Plasma was recovered by centrifugation and
stored at 4 °C.
Lipoprotein and apolipoprotein analysis
Cholesterol (Monotest, CHOD-PAP) and triacylglycerols
(GPO-PAP) were measured using reagents from Boehringer
Mannheim (Germany). VLDL-cholesterol was determined by
preparative ultracentrifugation at d20°c = 1.0063 kg/1 (2.35
• 108g · min) as described (13). High density lipoprotein cho-
lesterol was measured after precipitation of apolipoprotein B-
containing lipoproteins with sodium phosphotungstic acid and
MgCl2 (13). LDL-cholesterol was calculated as the difference
between total cholesterol and the sum of VLDL-cholesterol and
high density lipoprotein cholesterol (13).
') Homozygosity for apolipoprotein E2 is highly suggestive of
type III hyperlipoproteinaemia, but other apolipoprotein E
phenotypes do not rule out the disorder.
Apolipoproteins B and E were determined by kinetic nephelo-
metry (Array Protein System, Beckman Diagnostics, Brea, CA).
The assay for apolipoprotein B was calibrated with the apoli-
poprotein calibrator APO CAL from Beckman Diagnostics,
which is standardized against the WHO international reference
material. The assay for apolipoprotein E was also calibrated
using a standard provided by Beckman. Electrophoresis of
lipoproteins was carried out as described by Neubeck et al. (14).
Apolipoprptein E phenotyping was performed by isolectric
focusing of delipidated VLDL (15) or by immunoblotting (16).
Subjects
Fourty patients (18 male, 22 female, age range 31—72 years)
with type III hyperupoprpteinaemia recruited at the Depart-
ment of Internal Medicine in Heidelberg and at the Centre of
Internal Medicine in Frankfurt were studied. Among these type
III patients, 16 suffered from peripheral vascular disease. Cere-
brovascular disease and coronary artery disease were present
in 9 and 6 cases, respectively. The diagnosis of type III hyper-
lipoproteinaemia was made if all the following criteria were
met: cholesterol above 5.2 mmol/1 and/or triacylglycerols above
2.3 mmol/1; the ratio of VLDL-cholesterol to plasma triacyl-
glycerols [mmol/l] greater than 0.68; and detection of VLDL
particles with ß-mobility. Phenotypically, all type III patients
were E2/2 homozygotes. As controls, we studied samples from
patients with primary hyperlipoproteinaeniia other than type
III. Because we wished to simulate the diagnostic situation, we
selected control samples that were suggestive of type IirHyper-
lipoproteinaemia on the basis of their cholesterol and triacyl-
glycerol concentrations. In all control samples the ratio of
VLDL-cholesterol to total triacylglycerols was lower than 0.68,
and none had the apolipoprotein E2/2 phenotype. Twenty eight
controls had type IV hyperlipopfoteinaemia, 17 had type lib
and 3 had type Ila hyperlipoproteinaernia; eleven individuals
suffered from coronary artery disease, as diagnosed clinically
and by an exercise electrocardiogram.
Results
Table 1 contains mean lipid and apolipoprotein con-
centrations in the two patient groups. As a result of
matching, the groups were similar with respect to
cholesterol and triacylglycerols. In spite of this, apo-
lipoprotein B was lower and apolipoprotein E was
higher in type III subjects than in non-type III sub-
jects. Consequently, the apolipoprotein E/B ratio was
different. Figure 1 shows that the apolipoprotein E/B
ratio allows almost complete discrimination of the
groups. Using a threshold value of 0.09 for the apo-
lipoprotein E/B ratio, type III hyperlipoproteinaemia
would be detected with a sensitivity of 95%, the
specificity being 88%. If one assumes that the prev-
alence of type III hyperlipoproteinaemia is 1 in 100
patients with hyperlipidaemia, the predictive value of
the positive test (apolipoprotein E/B > 0.09) is 0.07,
the predictive value of the negative test is 1.00, and
diagnostic efficacy is 0.88.
In plasma, a considerable fraction of apolipoprotein
E is associated with triacylglycerol-rich lipoproteins.
Therefore, increases in triacyclglycerols are generally
attended by increases in apolipoprotein E. In fact, in
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type III other types
Fig. 1. Apolipoprotein E to apolipoprotein B ratio in 40 pa-
tients with type III hyperlipoproteinaemia (closed cir-
cles) and in 48 patients with other types of hyperlipo-
proteinaemia (open squares), matched for cholesterol
and triacylglycerols.
type III patients as well as in the controls, the apoli-
poprotein E/B ratio was positively correlated with
triacylglycerols, the correlation coefficients being
0.483 and 0.632, respectively. However, as shown in
figure 2, at any given triacylglycerol concentration
the apolipoprotein E/B ratio was higher in type III
patients than in the control group. Figure 2 also
illustrates that if the apolipoprotein E/B cut-off is set
in favour of maximal sensitivity, e.g. at 0.07, triacyl-
glycerol concentrations may be disregarded. In con-
trast, if specificity is to be increased, the apolipopro-
tein E/B cut-off has to be adjusted for triacyclglycer-
ols, tentative threshold values being 0.09 in samples










Fig. 2. Apolipoprotein Ε to apolipoprotein Β ratio in 40 pa-
tients with type III hyperlipoproteinaemia (closed cir-
cles, solid line) and in 48 patients with other types of
hyperlipoproteinaemia (open squares, dashed line) plot-
ted versus plasma triacylglycerols.
Equations of the regression lines are as follows:
a) type III hyperlipoproteinaemia (solid line): apolipo-
protein E/B = 0.013 · triacylglycerols + 0.14;
r = 0.483;
b) other types of hyperlipoproteinaemia (dashed line):
apolipoprotein E/B = 0.009 · triacylglycerols + 0.009;
r = 0.632.
Discussion
Our data show that apolipoprotein Ε is markedly
increased in type III hyperlipoproteinaemia, while
apolipoprotein B is low or normal. This constellation
is not only seen in type III hyperlipoproteinaemia,
but also in normolipidaemic E2/2 homozygotes, and
it relates to the well-documented functional abnor-
mality of apolipoprotein E2 (5—7).
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Apart from several rare variants (17 — 23), there are
three common alleles at the apolipoprotein E gene
locus (ε2, ε3, and ε4), encoding for the isoforms E2,
E3, and E4 (24). More than 90% of patients with
type III hyperlipoproteinaemia are of the E2/2 phe-
notype (9). In vitro, apolipoprotein E2 is defective in
binding to apolipoprotein B,E-receptors (5 — 7). Since
the clearance of both chylomicron and VLDL rem-
nants depends on apolipoprotein E, even normolipi-
daemic apolipoprotein E2/2 homozygotes accumulate
small amounts of remnant particles in the circulation
(dysbetalipoproteinaemia). The flux of dietary cho-
lesterol into the liver is decreased and hepatic apoli-
poprotein Β,Ε-receptors are up-regulated. Therefore,
E2 homozygotes have low LDL-cholesterol and apo-
lipoprotein Β concentrations. In contrast, the presence
of at least one apolipoprotein E4 allele is associated
with high levels of LDL-cholesterol and apolipopro-
tein Β (1, 9-11).'. \
In type III hyperlipoproteinaemia, remnant accumu-
lation is largely accentuated by the presence of at least
one factor other than apolipoprotein E2 homozygos-
ity, exogenous or genetic. In general, the remnant
particles found in type III hyperlipoproteinaemia im-
pose a very high risk of atherosclerosis, β-VLDL from
subjects with type III hyperlipoproteinaemia are av-
idly taken up by macrophages, which are thereby
converted into lipid-storing foam cells, one of the key
cell types of atherosclerotic lesions (25). Since type
III hyperlipoproteinaemia responds well to the elim-
ination of disease-promoting conditions (1) and to
dietary treatment (26), its recognition is of vital im-
portance for the affected individuals.
Unfortunately, there is hardly any simple and straight-
forward screening method for type III hyperlipopro-
teinaemia in the clinical laboratory. Thus, many pa-
tients with this disorder have so far remained undi-
agnosed.
Generally speaking, samples in which both cholesterol
and triacylglycerols are about two- to fourfold the
normal value are suggestive of type III hyperlipopro-
teinaemia. However, in routine practice, methods such
as ultracentrifugation or apolipoprotein E phenotyp-
ing are not available for confirming or rejecting the
diagnosis of type III hyperlipoproteinaemia. There-
fore, a simple, yet sensitive test is required to identify
patients with type III hyperlipoproteinaemia. In the
present study, we show that the apolipoprotein E/
apolipoprotein Β ratio almost completely discrimi-
nates between type III hyperlipoproteinaemia and
other types of hyperlipoproteinaemia with approxi-
mately the same concentrations of total cholesterol,
triacylglycerols and high density lipoprotein choles-
terol. Using a cut-off point of 0.09 for the apolipo-
protein E/B ratio, sensitivity and specificity would be
95% and 88%, respectively. Assuming that the prev-
alence of type III hyperlipoproteinaemia is 1 in 100
patients with hyperlipidaemia, the predictive value of
the positive test (apolipoprotein E/B > 0.09) would
be 0.07, the predictive value of the negative test would
be 1.00 and diagnostic efficacy would be 0.88. These
estimates are very close to the characteristics of tests
applied to the screening for rare inborn errors of
metabolism such as phenylketonuria, cystic fibrosis,
hypothyroidism or muscular dystrophies (27).
Since automated assays for both apolipoprotein Β
and apolipoprotein Ε have recently become available,
these determinations can conveniently be performed
in any clinical laboratory. The values for the apoli-
poprotein Ε to apolipoprotein Β ratio obtained in
this work do, of course, depend on the immunoassay
method used. Our apolipoprotein B immuiioassay was
calibrated against the WHO international reference
material. At present, no such material is available for
apolipoprotein E. Therefore, the cut-off values de-
rived here may need adjustment in the future. In the
meantime, laboratories using our approach to the
screening for type III hyperlipoproteinaemia will have
to establish own normal ranges.
The apolipoprotein E to apolipoprotein Β ratio does
not replace the classical means of confirming type III
hyperlipoproteinaemia, but it may prove suitable as
a first line screening parameter for identifying patients
in need of additional testing with technically demand-
ing procedures such as ultracentrifugation or apoli-
poprotein E phenotyping.
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